MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial-Reference-Cited by-同舟云学术

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial

Published:2009-03 Issue:3 Volume:60 Page:870-877
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Chung Lorinda,Shapiro Lee,Fiorentino David,Baron Murray,Shanahan Joseph,Sule Sangeeta,Hsu Vivien,Rothfield Naomi,Steen Virginia,Martin Richard W.,Smith Edwin,Mayes Maureen,Simms Robert,Pope Janet,Kahaleh Bashar,Csuka M. E.,Gruber Barry,Collier David,Sweiss Nadera,Gilbert Adam,Dechow Frederick J.,Gregory Jeffrey,Wigley Fredrick M.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference30 articles.

1. Different factors influencing the expression of Raynaud's phenomenon in men and women;Fraenkel;Arthritis Rheum,1999

2. Raynaud's phenomenon;Block;Lancet,2001

3. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma;Hummers;Rheum Dis Clin North Am,2003

4. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon;Merkel;Arthritis Rheum,2002

5. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease;Franks;Lancet,1982

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic literature review to inform the Portuguese recommendations for the management of Raynaud’s phenomenon and digital ulcers in systemic sclerosis and other connective tissue diseases;ARP Rheumatology;2024-06-30

2. Practical Approach to the Patient with Raynaud’s Phenomenon: Primary Versus Secondary Raynaud’s Phenomenon;Raynaud’s Phenomenon;2024

3. Digital Ulcers and Acute Digital Ischemia;Raynaud’s Phenomenon;2024

4. Drug Therapy;Raynaud’s Phenomenon;2024

5. Clinical Outcome Measures in Raynaud’s Phenomenon;Raynaud’s Phenomenon;2024